Four Europeans are diagnosed with cancer every minute. Addressing this challenge requires sustained focus on therapeutic innovation. The European Medicines Agency has now published a Horizon Scanning Report specifically focused on radiopharmaceuticals. Excellent news for the industry and a significant recognition of therapeutic nuclear medicine’s role in cancer care.
As the voice of the European nuclear medicine industry, Nuclear Medicine Europe has maintained ongoing dialogue with EMA through our working groups, contributing to consultations and regulatory discussions on radiopharmaceuticals and therapeutic applications. EMA’s dedicated focus on this sector – which will propose recommendations to shape future regulatory frameworks – is recognition of the field’s importance and potential.
We look forward to continuing our role in ensuring industry expertise informs the development of frameworks that enable innovation while ensuring patient access to these life-saving therapies.
See EMA’s recommendations for the future of radiopharmaceuticals in Europe.